Jerome Ritz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/251704/publications.pdf

Version: 2024-02-01

617	50,408	735 120	2127 203
papers	citations	h-index	g-index

632	632	632	36230
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 547, 217-221.	27.8	2,112
2	Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. New England Journal of Medicine, 2011, 365, 2055-2066.	27.0	996
3	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565, 234-239.	27.8	956
4	Biology and clinical relevance of human natural killer cells. Blood, 1990, 76, 2421-2438.	1.4	869
5	Expression of Epsteinâ€“Barr Virus Transformationâ€“Associated Genes in Tissues of Patients with EBV Lymphoproliferative Disease. New England Journal of Medicine, 1989, 321, 1080-1085.	27.0	804
6	Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell, 1985, 42, 581-588.	28.9	730
7	A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature, 1980, 283, 583-585.	27.8	700
8	Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma. New England Journal of Medicine, 1991, 325, 1525-1533.	27.0	678
9	IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood, 2006, 108, 1571-1579.	1.4	651
10	Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression.. Journal of Experimental Medicine, 1979, 150, 1472-1482.	8.5	610
11	The elusive nature and function of mesenchymal stem cells. Nature Reviews Molecular Cell Biology, 2011, 12, 126-131.	37.0	544
12	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	9.4	503
13	Expression of myeloid differentiation antigens on normal and malignant myeloid cells.. Journal of Clinical Investigation, 1981, 68, 932-941.	8.2	491
14	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. New England Journal of Medicine, 2016, 375, 143-153.	27.0	488
15	Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer. New England Journal of Medicine, 1991, 324, 1773-1778.	27.0	481
16	Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood, 2005, 106, 2903-2911.	1.4	430
17	Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, 108, 756-762.	1.4	422
18	Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.. Journal of Experimental Medicine, 1990, 171, 1509-1526.	8.5	418

#	Article	IF	Citations
19	Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. Science Translational Medicine, 2013, 5, 179ra43.	12.4	401
20	A unique cell surface antigen identifying lymphoid malignancies of B cell origin.. Journal of Clinical Investigation, 1981, 67, 134-140.	8.2	368
21	Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clinical Cancer Research, 1997, 3, 409-17.	7.0	365
22	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood, 2005, 105, 2973-2978.	1.4	361
23	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 2691-2698.	1.6	359
24	A Modified Î³-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. New England Journal of Medicine, 2014, 371, 1407-1417.	27.0	358
25	ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death. New England Journal of Medicine, 2013, 369, 529-539.	27.0	339
26	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2017, 35, 1598-1605.	1.6	339
27	Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.. Journal of Experimental Medicine, 1992, 175, 779-788.	8.5	337
28	Current issues in chronic graft-versus-host disease. Blood, 2014, 124, 374-384.	1.4	336
29	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 211-234.	2.0	328
30	Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. Blood, 1999, 94, 3325-3333.	1.4	319
31	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 252-257.	7.1	314
32	A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood, 2012, 120, 905-913.	1.4	310
33	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. Blood, 1998, 91, 3671-3680.	1.4	304
34	Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science, 1994, 266, 1039-1042.	12.6	303
35	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsonâ€™s Disease. New England Journal of Medicine, 2020, 382, 1926-1932.	27.0	298
36	Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood, 2004, 103, 2771-2778.	1.4	296

#	Article	IF	Citations
37	Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood, 1981, 58, 141-152.	1.4	292
38	Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Experimental Hematology, 1996, 24, 406-15.	0.4	290
39	Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature, 1985, 317, 428-430.	27.8	288
40	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood, 2014, 124, 453-462.	1.4	286
41	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood, 2009, 113, 3865-3874.	1.4	285
42	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood, 2005, 105, 1810-1814.	1.4	280
43	Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood, 2013, 122, 3074-3081.	1.4	280
44	Prolonged Disease-Free Survival after Autologous Bone Marrow Transplantation in Patients with Non-Hodgkin's Lymphoma with a Poor Prognosis. New England Journal of Medicine, 1987, 316, 1499-1505.	27.0	264
45	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood, 2016, 128, 195-203.	1.4	259
46	Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes.. Journal of Clinical Investigation, 1985, 75, 932-943.	8.2	259
47	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Antiâ€"T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Diseaseâ€"Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 4003-4011.	1.6	258
48	PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Human Molecular Genetics, 1999, 8, 185-193.	2.9	254
49	Post-Transcriptional Genetic Silencing ofBCL11Ato Treat Sickle Cell Disease. New England Journal of Medicine, 2021, 384, 205-215.	27.0	250
50	Biology and clinical relevance of human natural killer cells. Blood, 1990, 76, 2421-38.	1.4	248
51	TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood, 1996, 88, 4252-4258.	1.4	238
52	High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease. Clinical Cancer Research, 2007, 13, 6107-6114.	7.0	238
53	Interferon-Î³-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. OncoImmunology, 2015, 4, e1008824.	4.6	238
54	Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clinical Cancer Research, 1999, 5, 9-16.	7.0	237

#	Article	IF	Citations
55	MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1285-1290.	7.1	235
56	Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nature Medicine, 1999, 5, 444-447.	30.7	233
57	Lymphokine-activated killer cell activity. Trends in Immunology, 1987, 8, 178-181.	7.5	229
58	Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood, 1983, 61, 628-639.	1.4	228
59	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
60	AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN CALLA-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA AFTER IN-VITRO TREATMENT WITH J5 MONOCLONAL ANTIBODY AND COMPLEMENT. Lancet, The, 1982, 320, 60-63.	13.7	224
61	B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.. Journal of Clinical Investigation, 1997, 100, 3140-3148.	8.2	224
62	Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood, 1982, 59, 1-11.	1.4	223
63	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood, 2012, 119, 1570-1580.	1.4	221
64	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunology Research, 2019, 7, 100-112.	3.4	220
65	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. Journal of Clinical Oncology, 2020, 38, 3095-3106.	1.6	216
66	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. Journal of Clinical Investigation, 2010, 120, 1479-1493.	8.2	212
67	High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood, 1996, 88, 2780-2786.	1.4	210
68	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 2017, 129, 1380-1388.	1.4	209
69	Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood, 2005, 106, 4389-4396.	1.4	208
70	Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood, 1980, 55, 395-402.	1.4	208
71	Epsteinâ€“Barr Virusâ€“Associated B-Cell Proliferations of Diverse Clonal Origins after Bone Marrow Transplantation in a 12-Year-Old Patient with Severe Combined Immunodeficiency. New England Journal of Medicine, 1985, 312, 1151-1159.	27.0	207
72	A subset of natural killer cells in peripheral blood displays a mature T cell phenotype.. Journal of Experimental Medicine, 1986, 164, 351-356.	8.5	207

#	Article	IF	Citations
73	Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood, 1981, 57, 1105-1110.	1.4	206
74	CD3-negative natural killer cells express Îµ TCR as part of a novel molecular complex. Nature, 1989, 341, 159-162.	27.8	202
75	Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood, 1981, 58, 648-652.	1.4	200
76	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood, 1996, 88, 2228-2235.	1.4	197
77	Identification and molecular cloning of the human Blym transforming gene activated in Burkitt's lymphomas. Nature, 1983, 305, 112-116.	27.8	194
78	SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood, 2006, 108, 2726-2735.	1.4	194
79	T-cellâ€“depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood, 2001, 98, 934-939.	1.4	193
80	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 1992, 79, 517-526.	1.4	191
81	Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature, 1983, 301, 158-160.	27.8	189
82	Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2006, 12, 1047-1055.	2.0	181
83	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 1999, 17, 3128-3135.	1.6	180
84	Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood, 2011, 118, 6691-6697.	1.4	180
85	Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. Journal of Immunology, 1987, 139, 3306-13.	0.8	180
86	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood, 2014, 123, 3988-3998.	1.4	179
87	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood, 2000, 95, 3183-3190.	1.4	177
88	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood, 2016, 128, 130-137.	1.4	176
89	CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology, 1999, 97, 159-165.	4.4	175
90	High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.. Journal of Clinical Oncology, 1998, 16, 13-18.	1.6	174

#	Article	IF	Citations
91	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. Journal of Clinical Investigation, 2014, 124, 4867-4876.	8.2	173
92	Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood, 1991, 77, 2524-2529.	1.4	168
93	Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. Journal of Immunology, 1990, 145, 3194-201.	0.8	167
94	Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood, 1992, 79, 576-585.	1.4	166
95	Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4819-4823.	7.1	164
96	Characterization of Functional Surface Structures on Human Natural Killer Cells. Advances in Immunology, 1988, 42, 181-211.	2.2	163
97	Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation. Journal of Experimental Medicine, 2004, 199, 1133-1142.	8.5	162
98	Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science, 1985, 228, 1540-1543.	12.6	161
99	Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2274-2278.	7.1	161
100	Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 565-574.	2.0	160
101	Probing circulating tumor cells in microfluidics. Lab on A Chip, 2013, 13, 602.	6.0	156
102	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood, 2017, 129, 2186-2197.	1.4	156
103	Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Human Immunology, 1981, 3, 247-259.	2.4	149
104	Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis.. Journal of Experimental Medicine, 1985, 162, 1771-1787.	8.5	149
105	Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood, 2004, 103, 353-359.	1.4	149
106	Specific release of proteoglycans from human natural killer cells during target lysis. Nature, 1985, 318, 289-291.	27.8	148
107	Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation. Blood, 1994, 84, 964-971.	1.4	146
108	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood, 2016, 127, 2144-2154.	1.4	145

#	Article	IF	Citations
109	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood, 2016, 127, 646-657.	1.4	145
110	Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood, 2004, 104, 1224-1226.	1.4	140
111	Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood, 1986, 67, 722-728.	1.4	138
112	Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood, 2000, 95, 352-359.	1.4	138
113	Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 655-664.	2.0	135
114	Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation. Journal of Clinical Oncology, 2012, 30, 3202-3208.	1.6	135
115	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2017, 7, 852-867.	9.4	132
116	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. British Journal of Haematology, 2002, 117, 828-834.	2.5	131
117	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clinical Cancer Research, 2017, 23, 3510-3519.	7.0	130
118	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood, 2019, 134, 22-29.	1.4	129
119	Surface antigens on malignant Sezary and T-CLL cells correspond to those of mature T cells. Blood, 1981, 57, 526-530.	1.4	128
120	Gene Expression Profiles of B-lineage Adult Acute Lymphocytic Leukemia Reveal Genetic Patterns that Identify Lineage Derivation and Distinct Mechanisms of Transformation. Clinical Cancer Research, 2005, 11, 7209-7219.	7.0	128
121	Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells.. Journal of Experimental Medicine, 1994, 180, 241-251.	8.5	127
122	Biomanufacturing for clinically advanced cell therapies. Nature Biomedical Engineering, 2018, 2, 362-376.	22.5	127
123	B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood, 2012, 120, 2529-2536.	1.4	126
124	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight, 2016, 1, e89278.	5.0	126
125	Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. European Journal of Immunology, 1992, 22, 1-6.	2.9	122
126	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-Î² production. Blood, 2017, 129, 2570-2580.	1.4	122

#	Article	IF	Citations
127	Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. Journal of Clinical Investigation, 2000, 106, 705-714.	8.2	121
128	Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function.. Journal of Experimental Medicine, 1983, 158, 1547-1560.	8.5	116
129	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood, 2011, 117, 2275-2283.	1.4	115
130	Interleukin 2 signaling involves the phosphorylation of Stat proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7779-7783.	7.1	113
131	Predictors of Improved Progression-Free Survival After Nonmyeloablative Allogeneic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2006, 12, 1056-1064.	2.0	110
132	Comparative Outcomes of T-Cellâ€“Depleted and Nonâ€“T-Cellâ€“Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion. Journal of Clinical Oncology, 1999, 17, 561-561.	1.6	108
133	Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood, 2001, 98, 1116-1121.	1.4	107
134	Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biology of Blood and Marrow Transplantation, 2002, 8, 625-632.	2.0	107
135	Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood, 2010, 115, 4111-4119.	1.4	107
136	NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biology of Blood and Marrow Transplantation, 2010, 16, 565-586.	2.0	107
137	Aberrant B-cell homeostasis in chronic GVHD. Blood, 2015, 125, 1703-1707.	1.4	107
138	Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15825-15830.	7.1	105
139	Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplantation, 2011, 46, 659-667.	2.4	104
140	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood, 2013, 122, 1510-1517.	1.4	104
141	Role of the CD40 and CD95 (APOâ€1/Fas) antigens in the apoptosis of human Bâ€cell malignancies. British Journal of Haematology, 1997, 97, 409-417.	2.5	103
142	Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial.. Journal of Clinical Oncology, 1995, 13, 239-250.	1.6	102
143	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood, 2015, 125, 4085-4094.	1.4	101
144	Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood, 1990, 75, 296-304.	1.4	99

#	Article	IF	Citations
145	CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7492-7497.	7.1	99
146	Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood, 2017, 129, 22-29.	1.4	98
147	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	12.8	98
148	Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA).. Journal of Experimental Medicine, 1983, 157, 114-129.	8.5	97
149	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood, 1991, 78, 2759-2767.	1.4	97
150	Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia, 2013, 27, 362-369.	7.2	95
151	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood, 2016, 128, 1013-1017.	1.4	95
152	Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood, 1991, 77, 712-720.	1.4	94
153	Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood, 2005, 105, 3945-3950.	1.4	94
154	Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.. Journal of Clinical Investigation, 1997, 100, 855-866.	8.2	94
155	Functional Consequences of APO-1/Fas (CD95) Antigen Expression by Normal and Neoplastic Hematopoietic Cells. Leukemia and Lymphoma, 1995, 17, 51-61.	1.3	93
156	Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood, 2007, 109, 1355-1362.	1.4	93
157	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood, 2016, 127, 2489-2497.	1.4	92
158	Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nature Genetics, 2009, 41, 1341-1344.	21.4	91
159	Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. Journal of Immunology, 1980, 125, 1506-14.	0.8	91
160	CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission. Blood, 1997, 89, 3039-3047.	1.4	90
161	Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia.. Journal of Clinical Investigation, 1982, 70, 433-442.	8.2	90
162	Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clinical and Experimental Immunology, 2005, 141, 326-332.	2.6	89

#	Article	IF	Citations
163	Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leukemia Research, 1981, 5, 491-495.	0.8	88
164	Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Research, 1982, 42, 457-64.	0.9	88
165	Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood, 2009, 114, 3956-3959.	1.4	86
166	B Cells in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 16-23.	2.0	86
167	Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. Journal of Immunology, 1985, 135, 1020-5.	0.8	86
168	Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury. Biology of Blood and Marrow Transplantation, 2010, 16, 1180-1185.	2.0	85
169	CD2 regulates responsiveness of activated T cells to interleukin 12.. Journal of Experimental Medicine, 1995, 182, 721-731.	8.5	84
170	Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. Oncologist, 1996, 1, 88-97.	3.7	82
171	Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood, 2005, 106, 3639-3645.	1.4	79
172	Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical CordÂBlood and Unrelated Donor Grafts. Biology of Blood and Marrow Transplantation, 2012, 18, 805-812.	2.0	79
173	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. Journal of Clinical Oncology, 2022, 40, 189-201.	1.6	79
174	Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood, 2002, 99, 4610-4617.	1.4	78
175	Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood, 2014, 123, 1412-1421.	1.4	78
176	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood, 2017, 130, 91-94.	1.4	78
177	Expression of MY7 antigen on myeloid precursor cells. International Journal of Cell Cloning, 1983, 1, 33-48.	1.6	77
178	Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Research, 1985, 45, 499-503.	0.9	77
179	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood, 2000, 95, 3183-90.	1.4	77
180	Differential expression of CD8Î± and CD8Î² associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. Cellular Immunology, 1990, 131, 352-365.	3.0	76

#	Article	IF	Citations
181	Interferon-Î³ and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. European Journal of Immunology, 1997, 27, 647-652.	2.9	76
182	Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired inÂAdvanced Age. Biology of Blood and Marrow Transplantation, 2010, 16, 792-800.	2.0	76
183	Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood, 2011, 117, 4315-4322.	1.4	75
184	Costimulatory signals are required for optimal proliferation of human natural killer cells. Journal of Immunology, 1993, 150, 1705-14.	0.8	75
185	Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood, 1998, 91, 3671-80.	1.4	75
186	Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.. Journal of Clinical Oncology, 1997, 15, 723-734.	1.6	74
187	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. Blood, 2018, 132, 92-92.	1.4	74
188	Altered Interleukin-12 Responsiveness in Th1 and Th2 Cells Is Associated With the Differential Activation of STAT5 and STAT1. Blood, 1998, 91, 1341-1354.	1.4	73
189	Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood, 2004, 103, 656-663.	1.4	73
190	Preclinical regulatory validation of an engineered diaphragmatic tendon made with amniotic mesenchymal stem cells. Journal of Pediatric Surgery, 2011, 46, 57-61.	1.6	73
191	CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. Immunity, 2016, 45, 209-223.	14.3	73
192	A novel rapid single nucleotide polymorphism (SNP)â€“based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood, 2003, 101, 363-369.	1.4	72
193	Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation. Clinical Cancer Research, 2004, 10, 5065-5071.	7.0	72
194	Induction of Tumor Immunity Following Allogeneic Stem Cell Transplantation. Advances in Immunology, 2006, 90, 133-173.	2.2	72
195	Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Research, 1983, 43, 1389-94.	0.9	72
196	Leukemia-associated antigens in ALL. Blood, 1979, 54, 1240-1248.	1.4	69
197	Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion, 2003, 36, 782-788.	1.6	69
198	Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. Journal of Clinical Investigation, 2013, 123, 3756-3765.	8.2	69

#	Article	IF	Citations
199	MicroRNA Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells. PLoS ONE, 2011, 6, e16956.	2.5	69
200	Expression of a 26,000-dalton glycoprotein on activated human T cells. Cellular Immunology, 1981, 64, 192-199.	3.0	68
201	Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood, 1985, 65, 1064-1070.	1.4	68
202	Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biology of Blood and Marrow Transplantation, 1999, 5, 262-268.	2.0	68
203	CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Research, 2002, 62, 5517-5522.	0.9	68
204	PROPHYLAXIS OF BACTERIAL INFECTIONS WITH CIPROFLOXACIN IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION. Transplantation, 1991, 51, 630-635.	1.0	67
205	Epsteinâ€Barr virusâ€specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer, 2017, 123, 2642-2650.	4.1	67
206	Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. Journal of Immunology, 1982, 129, 1299-305.	0.8	67
207	Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood, 1993, 82, 2790-2796.	1.4	66
208	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood, 1990, 75, 2076-2084.	1.4	65
209	Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplantation, 2003, 32, 1145-1151.	2.4	65
210	Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplantation, 2000, 25, 623-632.	2.4	63
211	The Role of Natural Killer Cells in Immune Surveillance. New England Journal of Medicine, 1989, 320, 1748-1749.	27.0	62
212	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood, 2020, 135, 2182-2191.	1.4	62
213	Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biology of Blood and Marrow Transplantation, 2000, 6, 375-386.	2.0	61
214	Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol. Journal of Pediatric Surgery, 2008, 43, 1164-1169.	1.6	61
215	IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. Journal of Immunology, 1999, 162, 299-304.	0.8	60
216	Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 382-388.	2.0	58

#	Article	IF	Citations
217	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Advances, 2021, 5, 352-364.	5.2	58
218	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates.. Journal of Clinical Investigation, 1986, 77, 977-984.	8.2	58
219	A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 28-35.	2.0	57
220	Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1196-1204.	2.0	57
221	Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. Biology of Blood and Marrow Transplantation, 2015, 21, 873-880.	2.0	56
222	Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood, 1993, 81, 1651-1657.	1.4	55
223	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. Journal of Clinical Investigation, 2020, 130, 4624-4636.	8.2	55
224	Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. Journal of Immunology, 1996, 157, 1886-93.	0.8	55
225	HEPATIC DYSFUNCTION FOLLOWING T-CELL-DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1991, 52, 1014-1019.	1.0	54
226	Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells. Clinical Cancer Research, 2005, 11, 4504-4511.	7.0	54
227	Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. American Journal of Pathology, 1996, 148, 847-53.	3.8	54
228	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood, 1991, 77, 2404-2412.	1.4	53
229	Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature, 2021, 590, 157-162.	27.8	53
230	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight, 2017, 2, .	5.0	53
231	Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. Blood, 1992, 80, 1511-1520.	1.4	52
232	Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. British Journal of Haematology, 2007, 139, 504-507.	2.5	52
233	Efficacious Immune Therapy in Chronic Myelogenous Leukemia (CML) Recognizes Antigens That Are Expressed on CML Progenitor Cells. Cancer Research, 2010, 70, 906-915.	0.9	52
234	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Advances, 2019, 3, 2199-2204.	5.2	52

#	Article	IF	Citations
235	Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11348-11353.	7.1	51
236	Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. Bone Marrow Transplantation, 2013, 48, 593-597.	2.4	51
237	Signaling by the Epsteinâ€“Barr virus LMP1 protein induces potent cytotoxic CD4 ⁺ and CD8 ⁺ T cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E686-E695.	7.1	51
238	Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 1516-1521.	2.0	50
239	Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 183-190.	2.4	50
240	CD6+ Donor Marrow T-Cell Depletion as the Sole Form of Graft-Versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Bone Marrow Transplant From Unrelated Donors. Journal of Clinical Oncology, 2001, 19, 1152-1159.	1.6	49
241	Manufacturing development and clinical production of NKG2D chimeric antigen receptorâ€“expressing T cells for autologous adoptive cell therapy. Cytotherapy, 2018, 20, 952-963.	0.7	49
242	Further Analysis of Interleukin-2 Receptor Subunit Expression on the Different Human Peripheral Blood Mononuclear Cell Subsets. Blood, 1998, 91, 165-172.	1.4	48
243	A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1737-1743.	2.0	48
244	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. Journal of Clinical Investigation, 2022, 132, .	8.2	48
245	Expression of CD30 in patients with acute graft-versus-host disease. Blood, 2012, 120, 691-696.	1.4	47
246	Nextâ€generation sequencingâ€based detection of circulating tumour <scp>DNA</scp> After allogeneic stem cell transplantation for lymphoma. British Journal of Haematology, 2016, 175, 841-850.	2.5	47
247	Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. Blood, 1994, 83, 184-190.	1.4	46
248	Factors associated with bronchiolitis obliterans syndrome and chronic graftâ€versusâ€host disease after allogeneic hematopoietic cell transplantation. American Journal of Hematology, 2014, 89, 404-409.	4.1	46
249	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Advances, 2020, 4, 122-126.	5.2	46
250	Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood, 1987, 69, 597-604.	1.4	46
251	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 1992, 79, 517-26.	1.4	46
252	Identification of a 140-kDa activation antigen as a target structure for a series of human cloned natural killer cell lines. European Journal of Immunology, 1984, 14, 844-852.	2.9	45

#	Article	IF	Citations
253	Function of the LFA-1 and T4 molecules in the direct activation of resting human B lymphocytes by T lymphocytes. European Journal of Immunology, 1986, 16, 1539-1543.	2.9	45
254	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation. Blood, 1997, 90, 4996-5001.	1.4	45
255	ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6919-6924.	7.1	45
256	Up-Regulation of Î±4Î²7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 1066-1076.	2.0	45
257	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 668-675.	2.0	45
258	Fc gamma RIIIA-mediated signaling involves src-family lck in human natural killer cells. Journal of Immunology, 1993, 151, 6794-800.	0.8	45
259	Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clinical Cancer Research, 2002, 8, 2052-60.	7.0	45
260	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood, 2011, 118, 5021-5030.	1.4	44
261	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Advances, 2019, 3, 2550-2561.	5.2	44
262	Enhancement of natural killer function through activation of the T11 E rosette receptor.. Journal of Clinical Investigation, 1987, 79, 305-308.	8.2	44
263	Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood, 1983, 61, 628-39.	1.4	44
264	Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood, 1981, 58, 141-52.	1.4	44
265	Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	44
266	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 ⁺ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica, 2016, 101, 499-505.	3.5	43
267	Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. Journal of Immunology, 1985, 135, 1746-51.	0.8	43
268	Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood, 1981, 58, 648-52.	1.4	43
269	Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. Journal of Allergy and Clinical Immunology, 2009, 124, 1062-1069.e4.	2.9	42
270	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. Journal of Neuro-Oncology, 2018, 137, 269-278.	2.9	42

#	Article	IF	Citations
271	Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.4	41
272	IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene, 1998, 16, 2503-2512.	5.9	41
273	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med, 2021, 2, 411-422.e5.	4.4	41
274	Current Challenges in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2010, 16, S146-S151.	2.0	40
275	Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.. Journal of Clinical Investigation, 1998, 102, 561-575.	8.2	40
276	Immune-Mediated Cytopenia following Bone Marrow Transplantation Case Reports and Review of the Literature. Medicine (United States), 1992, 71, 73-83.	1.0	38
277	THE PHENOTYPE AND RECONSTITUTION OF IMMUNOREGULATORY T CELL SUBSETS AFTER T CELL-DEPLETED ALLOGENEIC AND AUTOLOGOUS BONE MARROW TRANSPLANTATION. Transplantation, 1994, 57, 1465-1473.	1.0	38
278	The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. Journal of Immunology, 1985, 135, 672-8.	0.8	38
279	A Novel Mechanism of Alternative Promoter and Splicing Regulates the Epitope Generation of Tumor Antigen CML66-L. Journal of Immunology, 2004, 172, 651-660.	0.8	37
280	Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion. Clinical Cancer Research, 2010, 16, 2729-2739.	7.0	37
281	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2344-2353.	2.0	37
282	PREVENTION OF TRANSMISSION OF HEPATITIS C VIRUS IN BONE MARROW TRANSPLANTATION BY TREATING THE DONOR WITH??-INTERFERON1. Transplantation, 1996, 62, 1358-1360.	1.0	37
283	Mapping the evolution of TÂcell states during response and resistance to adoptive cellular therapy. Cell Reports, 2021, 37, 109992.	6.4	37
284	Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood, 2022, 139, 3546-3557.	1.4	37
285	Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood, 1994, 84, 964-71.	1.4	36
286	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood, 1981, 58, 333-336.	1.4	35
287	Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. Journal of Allergy and Clinical Immunology, 2008, 122, 1185-1193.	2.9	35
288	Validation of shortâ€term handling and storage conditions for marrow and peripheral blood stem cell products. Transfusion, 2011, 51, 137-147.	1.6	35

#	Article	IF	Citations
289	Induction of natural killer effectors from human thymus with recombinant IL-2. Journal of Immunology, 1988, 140, 3660-7.	0.8	35
290	Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood, 1994, 84, 2109-2114.	1.4	34
291	Expression of the IL-2 receptor gamma subunit in resting human CD4 T lymphocytes: mRNA is constitutively transcribed and the protein stored as an intracellular component. International Immunology, 1997, 9, 573-580.	4.0	34
292	Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation. Blood, 2001, 97, 3860-3866.	1.4	34
293	Biologic Activity of Autologous, Granulocyteâ€“Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	7.0	34
294	Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood, 2017, 129, 3256-3261.	1.4	34
295	Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody. Journal of Immunology, 1981, 126, 540-4.	0.8	34
296	Phosphorylation of src Family lck Tyrosine Kinase Following Interleukin-12 Activation of Human Natural Killer Cells. Cellular Immunology, 1995, 165, 211-216.	3.0	33
297	CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkinâ€™s lymphoma. Bone Marrow Transplantation, 1998, 21, 1177-1181.	2.4	33
298	Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation, 2002, 8, 139-144.	2.0	33
299	Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood, 2009, 113, 1681-1688.	1.4	33
300	Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosomeâ€“Encoded Minor Histocompatibility Epitopes. Clinical Cancer Research, 2010, 16, 1642-1651.	7.0	33
301	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood, 1996, 88, 2228-35.	1.4	33
302	Monoclonal Antibody-Purged Bone Marrow Transplantation Therapy for Multiple Myeloma. Leukemia and Lymphoma, 1995, 17, 87-93.	1.3	32
303	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Advances, 2019, 3, 969-979.	5.2	32
304	NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. Journal of Translational Autoimmunity, 2021, 4, 100103.	4.0	32
305	Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. Journal of Clinical Investigation, 2012, 122, 2369-2383.	8.2	32
306	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. Blood, 2016, 128, 4052-4052.	1.4	32

#	Article	IF	Citations
307	Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Research, 2003, 63, 2561-8.	0.9	32
308	Expression of the NKTa clonotype in a series of human natural killer clones with identical cytotoxic specificity.. Journal of Experimental Medicine, 1986, 163, 812-825.	8.5	31
309	Serologic Markers of Effective Tumor Immunity against Chronic Lymphocytic Leukemia Include Nonmutated B-Cell Antigens. Cancer Research, 2010, 70, 1344-1355.	0.9	31
310	Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. Blood, 1992, 79, 481-488.	1.4	30
311	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. Blood, 2006, 107, 197-204.	1.4	30
312	Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood, 1989, 74, 2203-2211.	1.4	30
313	DEPLETION OF T CELLS FROM HUMAN BONE MARROW USING MONOCLONAL ANTIBONDIES AND RABBIT COMPLEMENT. Transplantation, 1986, 42, 73-79.	1.0	29
314	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. Blood, 1998, 92, 2725-2729.	1.4	29
315	Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/Î²-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer Journal, 2014, 4, e178-e178.	6.2	29
316	Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: Mechanism, function, and implication for a potential novel therapeutic target. Experimental Hematology, 2014, 42, 307-316.e8.	0.4	29
317	Dramatic Expansion of HSCs: New Possibilities for HSC Transplants?. Cell Stem Cell, 2016, 18, 10-12.	11.1	29
318	Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Frontiers in Immunology, 2020, 11, 580328.	4.8	29
319	Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Natural Immunity, 1996, 15, 213-26.	0.1	29
320	Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica, 2018, 103, 522-530.	3.5	28
321	Human leukemia-associated antigen: relation to a family of surface glycoproteins. Journal of Immunology, 1980, 124, 2794-9.	0.8	28
322	Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clinical Cancer Research, 1996, 2, 493-9.	7.0	28
323	Synergistic Enhancement of Cell-Mediated Immunity by Interleukin-12 Plus Interleukin-2: Basis for Therapy of Cutaneous T Cell Lymphoma. Journal of Investigative Dermatology, 2002, 118, 366-371.	0.7	27
324	Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Experimental Hematology, 2003, 31, 924-933.	0.4	27

#	Article	IF	Citations
325	A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 1907-1913.	2.0	27
326	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica, 2016, 101, 1251-1259.	3.5	27
327	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood, 1990, 75, 2076-2084.	1.4	27
328	Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Progress in Hematology, 1981, 12, 187-225.	0.3	27
329	KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplantation, 2013, 48, 1000-1002.	2.4	26
330	A chronic ?postinfectious? fatigue syndrome associated with benign lymphoproliferation, B-cell proliferation, and active replication of human herpesvirus-6. Journal of Clinical Immunology, 1990, 10, 335-344.	3.8	25
331	Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. International Journal of Cancer, 1994, 57, 57-59.	5.1	24
332	Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Advances, 2019, 3, 984-994.	5.2	24
333	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood, 2021, 137, 3212-3217.	1.4	24
334	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 452-466.	1.2	24
335	Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cells.. Journal of Experimental Medicine, 1987, 165, 1749-1754.	8.5	23
336	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1733-1740.	2.0	23
337	Expression of Î±4Î²7 integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplantation, 2013, 48, 598-603.	2.4	22
338	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances, 2020, 4, 4113-4123.	5.2	22
339	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS ONE, 2015, 10, e0132564.	2.5	22
340	Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplantation, 1989, 4, 239-45.	2.4	22
341	High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood, 1996, 88, 2780-6.	1.4	22
342	CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood, 1997, 89, 3039-47.	1.4	22

#	Article	IF	Citations
343	Preparation and characterization of interleukin-2-gelonin conjugates made using different crosslinking reagents. Bioconjugate Chemistry, 1994, 5, 88-97.	3.6	21
344	Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood, 1995, 85, 1132-1137.	1.4	21
345	Identification of Cytolytic CD161â^'CD56+ Regulatory CD8 T Cells in Human Peripheral Blood. PLoS ONE, 2013, 8, e59545.	2.5	21
346	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	1.4	21
347	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Advances, 2021, 5, 5140-5149.	5.2	21
348	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells.. Journal of Clinical Investigation, 1986, 78, 666-673.	8.2	21
349	CD34+ CD38â^' and CD34+ HLA-DRâ^' cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy, 2006, 8, 399-407.	0.7	20
350	Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. American Journal of Hematology, 2010, 85, 967-971.	4.1	19
351	Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation. Transplantation, 2011, 92, 359-365.	1.0	19
352	White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. American Journal of Hematology, 2014, 89, 591-597.	4.1	19
353	Research Techniques Made Simple: Experimental Methodology for Single-Cell Mass Cytometry. Journal of Investigative Dermatology, 2017, 137, e31-e38.	0.7	19
354	Use of monoclonal antibodies in autologous and allogeneic bone marrow transplantation. Clinics in Haematology, 1983, 12, 813-832.	2.3	19
355	CD2-CD58 Interaction and the Control of T-Cell Interleukin-12 Responsiveness.. Annals of the New York Academy of Sciences, 1996, 795, 71-81.	3.8	18
356	TAL1 expression does not occur in the majority of T-ALL blasts. British Journal of Haematology, 1998, 102, 449-457.	2.5	18
357	A CD4+ T CELL CLONE SELECTED FROM A CML PATIENT AFTER DONOR LYMPHOCYTE INFUSION RECOGNIZES BCR-ABL BREAKPOINT PEPTIDES BUT NOT TUMOR CELLS1. Transplantation, 2001, 71, 1131-1137.	1.0	18
358	Low dose interleukinâ€2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. American Journal of Hematology, 2008, 83, 771-777.	4.1	18
359	Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 804-811.	2.0	18
360	Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respiratory Medicine, 2013, 107, 276-283.	2.9	18

#	Article	IF	Citations
361	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 2216-2223.	2.0	18
362	Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease. Frontiers in Oncology, 2019, 9, 141.	2.8	18
363	Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood, 1988, 72, 1163-1167.	1.4	17
364	Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leukemia Research, 1990, 14, 407-416.	0.8	17
365	Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion, 2003, 43, 614-621.	1.6	17
366	Bayesian Error-in-Variable Survival Model for the Analysis of GeneChip Arrays. Biometrics, 2005, 61, 488-497.	1.4	17
367	Sequential infusion of donorâ€derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2014, 89, 1092-1096.	4.1	17
368	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood, 2017, 130, 2889-2899.	1.4	17
369	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Science Translational Medicine, 2020, 12, .	12.4	17
370	Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acidâ€“immunoglobulin complexes in humans. Journal of Clinical Investigation, 2011, 121, 1574-1584.	8.2	17
371	Leukemia-associated antigens in ALL. Blood, 1979, 54, 1240-8.	1.4	17
372	Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. Journal of Clinical Immunology, 1995, 15, 51-57.	3.8	16
373	Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. Blood, 1996, 88, 2334-2341.	1.4	16
374	FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. British Journal of Haematology, 2005, 130, 43-50.	2.5	16
375	Targets of Tumor Immunity After Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Cancer Research, 2008, 14, 4997-4999.	7.0	16
376	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Advances, 2017, 1, 2269-2279.	5.2	16
377	Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease. Frontiers in Immunology, 2019, 10, 334.	4.8	16
378	BK virusâ€specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 1881-1893.	5.2	16

#	Article	IF	Citations
379	Comparative Antigenic Phenotypes of Normal and Leukemic Hemopoietic Precursor Cells Analysed with a â€œLibraryâ€•of Monoclonal Antibodies. Hamatologie Und Bluttransfusion, 1981, 26, 296-304.	0.0	16
380	Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	16
381	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood, 1990, 75, 2076-84.	1.4	16
382	THE PHENOTYPE AND RECONSTITUTION OF IMMUNOREGULATORY T CELL SUBSETS AFTER T CELL-DEPLETED ALLOGENEIC AND AUTOLOGOUS BONE MARROW TRANSPLANTATION. Transplantation, 1994, 57, 1465-1473.	1.0	15
383	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1499-1508.	3.5	15
384	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	2.0	15
385	Allogeneic hematopoietic cell transplantation outcomes in patients with Richterâ€™s transformation. Haematologica, 2021, 106, 3219-3222.	3.5	15
386	Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients. Blood, 2018, 132, 1023-1023.	1.4	15
387	Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplantation, 1990, 6, 329-31.	2.4	15
388	Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. Blood, 1998, 91, 165-72.	1.4	15
389	Human cell lines express multiple populations of Ia-like molecules. Human Immunology, 1981, 3, 67-76.	2.4	14
390	Natural killer-like function of activated T lymphocytes: Differential blocking effects of monoclonal antibodies specific for a 90-kDa clonotypic structure. Cellular Immunology, 1984, 86, 381-392.	3.0	14
391	Evidence against Tâ€cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology, 1996, 87, 402-407.	4.4	14
392	CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells. Experimental Hematology, 2001, 29, 209-220.	0.4	14
393	Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. Blood, 2002, 99, 4634-4637.	1.4	14
394	Quantitative Monitoring of BCR / ABL Transcript During STI-571 Therapy. Leukemia and Lymphoma, 2002, 43, 2281-2289.	1.3	14
395	ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA. Reviews in Clinical and Experimental Hematology, 2002, 6, 205-224.	0.1	14
396	Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood, 2007, 109, 2001-2007.	1.4	14

#	Article	IF	Citations
397	Detecting T-cell reactivity to whole cell vaccines. OncoImmunology, 2012, 1, 1095-1103.	4.6	14
398	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood, 2020, 135, 28-40.	1.4	14
399	Implications for Monitoring Natural Killer Responses following Allogeneic Bone Marrow Transplantation. Transplantation, 1986, 42, 252-256.	1.0	13
400	Clinical Significance ofbcr-ablGene Rearrangement Detected by the Polymerase Chain Reaction After Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 1993, 10, 1-8.	1.3	13
401	Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion, 2004, 44, 253-261.	1.6	13
402	Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunology, Immunotherapy, 2016, 65, 355-366.	4.2	13
403	Research Techniques Made Simple: Mass CytometryÂAnalysis Tools for Decrypting theÂComplexityÂof Biological Systems. Journal of Investigative Dermatology, 2017, 137, e43-e51.	0.7	13
404	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy, 2017, 19, 272-284.	0.7	13
405	Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation.. Journal of Clinical Investigation, 1994, 94, 481-488.	8.2	13
406	Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. JCI Insight, 2022, 7, .	5.0	13
407	Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. Haematologica, 2007, 92, 619-626.	3.5	12
408	Tregs, HSCT, and acute GVHD: up close and personal. Blood, 2013, 122, 1690-1691.	1.4	12
409	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). Blood, 2016, 128, 505-505.	1.4	12
410	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Advances, 2022, 6, 2183-2194.	5.2	12
411	R24 anti-GD3 ganglioside antibody can induce co-stimulation and prevent the induction of alloantigen-specific T cell clonal anergy. European Journal of Immunology, 1996, 26, 2149-2154.	2.9	11
412	Adult hematopoietic stem cell plasticity. Transfusion, 2002, 42, 1096-1101.	1.6	11
413	B-cell-directed therapy for chronic graft-versus-host disease. Haematologica, 2010, 95, 1811-1813.	3.5	11
414	Time to put the CAR-T before the horse. Blood, 2011, 118, 4761-4762.	1.4	11

#	Article	IF	Citations
415	Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood, 2012, 119, 3142-3150.	1.4	11
416	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica, 2013, 98, 964-970.	3.5	11
417	Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions. Clinical Cancer Research, 2015, 21, 1010-1018.	7.0	11
418	A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica, 2019, 104, e314-e317.	3.5	11
419	T Cell Clonal Dynamics Determined by High-Resolution TCR-Î² Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1567-1574.	2.0	11
420	Maturation and Phenotypic Heterogeneity of Human CD4+ Regulatory T Cells From Birth to Adulthood and After Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 570550.	4.8	11
421	Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nature Immunology, 2021, 22, 520-529.	14.5	11
422	FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation. Blood, 2011, 118, 653-653.	1.4	11
423	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. Blood, 1998, 91, 3671-3680.	1.4	11
424	Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood, 2000, 95, 352-359.	1.4	11
425	KIR-Ligand Incompatibility Is Not Associated with Relapse Reduction After Double Umbilical Cord Blood Transplantation,. Blood, 2011, 118, 4150-4150.	1.4	11
426	Tumor immunity: will new keys unlock the door?. Journal of Clinical Oncology, 1994, 12, 237-238.	1.6	10
427	Erythroid-lineageâ€“specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2008, 36, 1205-1215.	0.4	10
428	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clinical Immunology, 2019, 207, 18-23.	3.2	10
429	PD-1 Signaling Has a Critical Role in Maintaining Regulatory T Cell Homeostasis; Implication for Treg Depletion Therapy By PD-1 Blockade. Blood, 2015, 126, 848-848.	1.4	10
430	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood, 2000, 95, 3183-3190.	1.4	10
431	Interferon-Induced Changes in Expression of Antigens Defined by Monoclonal Antibodies on Malignant and Nonmalignant Mononuclear Hematopoietic Cells. Journal of Interferon Research, 1983, 3, 199-210.	1.2	9
432	Antigenic heterogeneity among burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leukemia Research, 1986, 10, 35-42.	0.8	9

#	Article	IF	Citations
433	Epstein-Barr Virus-Transformed B-Cell Line (DV-1) Derived from Bone Marrow of a Patient with Severe Combined Immunodeficiency and Immunoblastic Lymphoma. Pediatric Research, 1987, 21, 331-337.	2.3	9
434	Clonal evidence for the induction of NKH1 on activated human thymocytes. European Journal of Immunology, 1989, 19, 1735-1739.	2.9	9
435	THE EFFECT OF MINOR ABO MISMATCHES ON THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1994, 57, 780.	1.0	9
436	A clonal model for human CD8⁺ regulatory T cells: Unrestricted contactâ€dependent killing of activated CD4⁺ T cells. European Journal of Immunology, 2012, 42, 69-79.	2.9	9
437	Targeting PI3KÎ´ function for amelioration of murine chronic graft-versus-host disease. American Journal of Transplantation, 2019, 19, 1820-1830.	4.7	9
438	A Bortezomib-Based Regimen Offers Excellent Outcomes In Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: Phase II Results. Blood, 2013, 122, 3335-3335.	1.4	9
439	Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation. Blood, 2019, 134, 263-263.	1.4	9
440	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood, 1991, 78, 2759-67.	1.4	9
441	Revealing Tumor Immunity after Hematopoietic Stem Cell Transplantation. Clinical Cancer Research, 2009, 15, 4515-4517.	7.0	8
442	Engineered Memory-like NK Cars Targeting a Neoepitope Derived from Intracellular NPM1c Exhibit Potent Activity and Specificity Against Acute Myeloid Leukemia. Blood, 2020, 136, 3-4.	1.4	8
443	Mixed Chimerism Following Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease Prevents Intravascular Hemolysis and Restores Endothelial Function.. Blood, 2004, 104, 1679-1679.	1.4	8
444	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunology Research, 2021, 9, 1465-1475.	3.4	8
445	Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood, 1984, 64, 662-6.	1.4	8
446	Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood, 1988, 72, 1163-1167.	1.4	8
447	Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Advances, 2022, 6, 4392-4402.	5.2	8
448	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 32.e1-32.e10.	1.2	7
449	Ultrastructural evidence that the granules of human natural killer cell clones store membrane in a nonbilayer phase. American Journal of Pathology, 1987, 127, 305-16.	3.8	7
450	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood, 1991, 77, 2404-12.	1.4	7

#	Article	IF	Citations
451	Clinical Applications of Monoclonal Antibodies in Acute Leukemia. Annals of the New York Academy of Sciences, 1984, 428, 308-317.	3.8	6
452	Functional surface structures on human natural killer cells. Klinische Wochenschrift, 1985, 63, 1189-1200.	0.6	6
453	Studying Human Regulatory T Cells In vivo: Fig. 1.. Clinical Cancer Research, 2006, 12, 5265-5267.	7.0	6
454	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood, 2018, 132, 749-749.	1.4	6
455	Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Blood, 2019, 134, 1930-1930.	1.4	6
456	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. Blood, 1985, 66, 961-6.	1.4	6
457	BET-bromodomain and EZH2 inhibitorâ€“treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood, 2022, 139, 2983-2997.	1.4	6
458	Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. Journal of Clinical Apheresis, 1995, 10, 139-143.	1.3	5
459	Autologous bone marrow transplantation therapy for multiple myeloma. European Journal of Haematology, 1989, 43, 157-163.	2.2	5
460	Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. Haematologica, 2016, 101, e30-e33.	3.5	5
461	Comparative analysis of cell therapy infusion workflows at clinical sites. Cytotherapy, 2021, 23, 285-292.	0.7	5
462	Application of Monoclonal Antibodies to Autologous Bone Marrow Transplantation. , 1984, , 185-206.		5
463	DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant. Blood, 2020, 136, 26-26.	1.4	5
464	Abstract 5631: Personal neoantigen-targeting vaccination generates neoepitope-specific T cell responses in tumors of patients with glioblastoma. Cancer Research, 2018, 78, 5631-5631.	0.9	5
465	The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation. Transplantation, 1994, 57, 1465-73.	1.0	5
466	Monoclonal anti-T cell (T12) antibody treatment of graft-versus-host disease in severe combined immunodeficiency: targeting of antibody and activation of complement on CD8+ cytotoxic T cell surfaces. Journal of Allergy and Clinical Immunology, 1991, 87, 1029-1033.	2.9	4
467	Reprint of: B Cells in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, S11-S18.	2.0	4
468	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biology of Blood and Marrow Transplantation, 2017, 23, 103-112.	2.0	4

#	Article	IF	Citations
469	Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells (cTFR) and Suppresses Circulating T Follicular Helper Cells (cTFH) in Patients with Chronic Gvhd. Biology of Blood and Marrow Transplantation, 2018, 24, S72.	2.0	4
470	Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Frontiers in Immunology, 2020, 11, 608485.	4.8	4
471	Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood, 2019, 134, 5603-5603.	1.4	4
472	Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation. Blood, 1994, 84, 964-971.	1.4	4
473	TREG and Tcon Dynamics after Allo-HSCT: Cgvhd Is Associated to Decreased NaÃ¯Ve and Stem Cell Memory Subsets with a Concomitant Increase in Terminally Differentiated T Cell Subsets. Blood, 2016, 128, 2229-2229.	1.4	4
474	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. Blood, 2016, 128, 667-667.	1.4	4
475	Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic Gvhd. Blood, 2018, 132, 606-606.	1.4	4
476	Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial. Blood, 2020, 136, 8-9.	1.4	4
477	Systemic Mastocytosis Associated With Presence of Rheumatoid Factor. JAMA - Journal of the American Medical Association, 1976, 235, 1586.	7.4	3
478	Lymphoma with clonal T-cell receptor gene rearrangement in a 25-year survivor of Hodgkin's disease. Cancer, 1987, 60, 2213-2218.	4.1	3
479	Altered Tyrosine Phosphorylation Via the Very Late Antigen (VLA)/Î²1 Integrin Stimulation Is Associated With Impaired T-Cell Signaling Through VLA-4 After Allogeneic Bone Marrow Transplantation. Blood, 1997, 90, 4222-4229.	1.4	3
480	Rituxan for steroid-refractory chronic GVHD. Biology of Blood and Marrow Transplantation, 2005, 11, 10-11.	2.0	3
481	Recipient T-Cell Repertoire Diversity after Double Umbilical Cord Transplantation Correlates with Non-Relapse Mortality and Survival. Biology of Blood and Marrow Transplantation, 2014, 20, S243-S244.	2.0	3
482	Personnel environmental monitoring during manufacture of manipulated cell therapy products. Cytotherapy, 2018, 20, S68.	0.7	3
483	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplantation, 2020, 55, 804-810.	2.4	3
484	Cell-Surface Antigens in Acute Leukemia. , 1982, , 1-21.		3
485	Autologous Bone Marrow Transplantation in Calla Positive Acute Lymphoblastic Leukemia. , 1984, , 255-264.		3
486	Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential. , 2018, , .		3

#	Article	IF	Citations
487	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. Blood, 2018, 132, 706-706.	1.4	3
488	Pre-Infusion Characteristics of the Predominant Cord Blood Unit Correlate with Hematopoietic Engraftment in the Setting of Non-Myeloablative Double Cord Blood Transplant (DCBT).. Blood, 2005, 106, 3027-3027.	1.4	3
489	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. Blood, 2012, 120, 311-311.	1.4	3
490	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. Blood, 2013, 122, 695-695.	1.4	3
491	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. Blood, 2016, 128, 986-986.	1.4	3
492	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 1992, 79, 517-526.	1.4	3
493	Patients Who Respond to Donor Lymphocyte Infusion (DLI) Have an Antibody Response Against PDC-E2, the Immunodominant Autoantigens of Primary Biliary Cirrhosis (PBC), but with Different Specificity.. Blood, 2005, 106, 3105-3105.	1.4	3
494	Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. Blood, 1994, 83, 184-190.	1.4	3
495	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. Blood, 2016, 128, 508-508.	1.4	3
496	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-NaÃ¯ve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. Blood, 2019, 134, 2015-2015.	1.4	3
497	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood, 1981, 58, 333-6.	1.4	3
498	Immune Reconstitution After Double Umbilical Cord Blood Stem Cell Transplantation: Comparison With Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, S233.	2.0	2
499	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Advances, 2018, 2, 1412-1416.	5.2	2
500	Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. Cancer Treatment and Research, 1988, 38, 265-283.	0.5	2
501	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood, 2018, 132, 1650-1650.	1.4	2
502	Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib. Blood, 2018, 132, 4413-4413.	1.4	2
503	Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease. Blood, 2019, 134, 4516-4516.	1.4	2
504	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. Blood, 2004, 104, 2251-2251.	1.4	2

#	Article	IF	Citations
505	Further Analysis of Interleukin-2 Receptor Subunit Expression on the Different Human Peripheral Blood Mononuclear Cell Subsets. Blood, 1998, 91, 165-172.	1.4	2
506	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	1.4	2
507	JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression. Blood, 2013, 122, 3472-3472.	1.4	2
508	Monoclonal Antibody Purged Autologous Bone Marrow Transplantation for Relapsed Non T-Cell Acute Lymphoblastic Leukemia. , 1986, , 266-274.		2
509	Monoclonal-Antibody-Purged Autologous Bone Marrow Transplantation for Relapsed Non-T-Cell Acute Lymphoblastic Leukemia in Childhood. Hamatologie Und Bluttransfusion, 1987, 31, 67-74.	0.0	2
510	Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 4486-4486.	1.4	2
511	Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood, 1989, 74, 2203-2211.	1.4	2
512	Prognostic Significance of the Surface Antigens Expressed by Leukemic Cells. Leukemia and Lymphoma, 1994, 13, 15-22.	1.3	1
513	Response to Helsby and Tingle. American Journal of Hematology, 2011, 86, 384-384.	4.1	1
514	Reconstitution of T Cell Immunity after Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1151-1152.	2.0	1
515	Genetic Predispositions, Management Strategies, and Clinical Outcomes in Adults with Hemophagocytic Lymphohistiocytosis (HLH) after Reduced-Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation (HSCT) at Dana-Farber Cancer Institute. Biology of Blood and Marrow Transplantation, 2019, 25, S398.	2.0	1
516	Dynamics of Immune Cell Reconstitution in Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide (PTCy). Biology of Blood and Marrow Transplantation, 2019, 25, S327-S328.	2.0	1
517	Immunomodulatory therapy improves outcome in multiple myeloma patients with clonal hematopoiesis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e15.	0.4	1
518	Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplantation, 2020, 55, 1821-1823.	2.4	1
519	NK-Associated and LFA-1 Antigens: Phenotypic and Functional Studies Utilizing Human NK Clones. , 1986, , 133-144.		1
520	In Vitro Treatment with Monoclonal Antibody Prior to Autologous Bone Marrow Transplantation in Acute Lymphoblastic Leukemia. Hamatologie Und Bluttransfusion, 1983, 28, 117-123.	0.0	1
521	Abstract LB-272: T-cell clonal dynamics determined by high resolution TCR-Î² sequencing in recipients of allogeneic hematopoietic cell transplantation. , 2020, , .		1
522	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). Blood, 2018, 132, 2110-2110.	1.4	1

#	Article	IF	Citations
523	Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease. Blood, 2019, 134, 4517-4517.	1.4	1
524	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. Blood, 2006, 108, 259-259.	1.4	1
525	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. Blood, 2007, 110, 166-166.	1.4	1
526	Autologous Peripheral Blood Stem Cell Products from Patients with Hematologic Malignancies Have Increased Frequency of Regulatory T Cells (CD4+FoxP3+ Treg).. Blood, 2008, 112, 2310-2310.	1.4	1
527	Donor B-Cell Alloantibody Deposition and Germinal Center Formation Are Required for the Development of Murine Chronic Gvhd and Bronchiolitis Obliterans. Blood, 2011, 118, 307-307.	1.4	1
528	Low-Dose IL-2 Induces Bcl2 Expression and Resistance To Apoptosis In CD4 Regulatory T Cells. Blood, 2013, 122, 3475-3475.	1.4	1
529	All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients. Blood, 2016, 128, 669-669.	1.4	1
530	Leukemia-associated antigens in ALL. Blood, 1979, 54, 1240-1248.	1.4	1
531	Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood, 1992, 79, 576-585.	1.4	1
532	Novel Myeloma-Associated Antigens Revealed in the Context of Successful Syngeneic Hematopoietic Stem Cell Transplantation. Blood, 2008, 112, 815-815.	1.4	1
533	Genetic Screening for Myeloma Cell Susceptibility to NK Cell Mediated Lysis Using Large Lentiviral shRNA Libraries. Blood, 2008, 112, 2900-2900.	1.4	1
534	Role of B Cells in Graft-Versus-Leukemia and Graft-Versus-Host Disease. Blood, 2013, 122, SCI-3-SCI-3.	1.4	1
535	Transplantation with anti-B1 monoclonal antibody and complement treated autologous bone marrow for relapsed B-cell non-Hodgkinâ€™s lymphoma. , 1985, , 537-547.		1
536	Serotherapy and Bone Marrow Transplantation. , 1985, , 493-504.		1
537	Activation of Natural Killer Function Through the T11/E Rosette Receptor. Hamatologie Und Bluttransfusion, 1987, 31, 347-350.	0.0	1
538	Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood, 1991, 77, 712-720.	1.4	1
539	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood, 1991, 77, 2404-2412.	1.4	1
540	Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood, 1991, 77, 2524-2529.	1.4	1

#	Article	IF	Citations
541	Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. Blood, 1992, 80, 1511-1520.	1.4	1
542	Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood, 1993, 82, 2790-2796.	1.4	1
543	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation. Blood, 1997, 90, 4996-5001.	1.4	1
544	Longitudinal Changes in the Intestinal Microbiome Composition Following Gut Decontamination in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients: A Pilot Study. Blood, 2019, 134, 5665-5665.	1.4	1
545	Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 34-35.	1.4	1
546	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. Blood, 2020, 136, 10-11.	1.4	1
547	801 ABSENCE OF COMMON ALL ANTIGEN ON NORMAL PLURIPOTENTIAL MYELOID, ERYTHROID AND GRANULOCYTE PROGENITORS. Pediatric Research, 1981, 15, 576-576.	2.3	0
548	Acute lymphoblastic leukemia: Use of immune markers in diagnosis, prognosis and therapy. Clinical Biochemistry, 1983, 16, 357.	1.9	0
549	Clonal Analysis of Natural Killer Cell Lineage and Function1. , 1986, , 19-33.		0
550	Chapter 10 Immunity to cancer. Advances in Oncobiology, 1996, 1, 207-219.	0.0	0
551	Development and Implementation of a Computerized System for Collection, Processing, and Administration of Cellular Therapy Products. Journal of Oncology Practice, 2012, 8, 262-266.	2.5	0
552	B and T cells in chronic graft-versus-host disease and graft-versus-leukemia. , 2013, , 299-326.		0
553	Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, S70-S71.	2.0	0
554	Prediction of Severe Acute Graft-Versus-Host Disease (GVHD) in Recipients of HLA Identical Hematopoietic Cell Transplantation (HCT) Using Donor Gene Expression Profiling. Biology of Blood and Marrow Transplantation, 2018, 24, S173-S174.	2.0	0
555	Developing a robust competency program for the GMP novel cell therapy laboratory in the cell manipulation core facility laboratory at Dana-Farber Cancer Institute, Boston. Cytotherapy, 2018, 20, S79.	0.7	0
556	Safety considerations in the generation of clinical grade autologous ips cell lines. Cytotherapy, 2018, 20, S21.	0.7	0
557	5-year performance data and robust flexibility of a computerized physician ordering system for collection, processing, and administration of cellular therapy products. Cytotherapy, 2018, 20, S17-S18.	0.7	0
558	How optimizing efficiency for autologous stem cell collection can set the stage for novel cell therapy growth in multiple departments. Cytotherapy, 2018, 20, S73-S74.	0.7	0

#	Article	IF	Citations
559	T Cellâ€“ and B Cellâ€“Mediated Pathology in Chronic Graft-Versus-Host Disease. , 2019, , 251-273.		0
560	Single Cell T Cell Maps of Donor Lymphocyte Infusion (DLI) Response and Resistance. Biology of Blood and Marrow Transplantation, 2019, 25, S48.	2.0	0
561	Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates. Biology of Blood and Marrow Transplantation, 2019, 25, S16-S17.	2.0	0
562	Making Room in the Parking Lot for More Cars - How Changes to Autologous Collection Targets for Patients with Multiple Myeloma Optimized Resource Utilization in the Apheresis Collection Center and Cell Storage Facility at Dana-Farber Cancer Institute. Biology of Blood and Marrow Transplantation, 2019, 25, S177-S178.	2.0	0
563	Comparing the functionality of proleukinÂ® and akron interleukin-2 through an analysis of key T cell subsets. Cytotherapy, 2020, 22, S121-S122.	0.7	0
564	Donor risk factors and recipient clinical impact of positive microbial contamination after bone marrow harvests - a large academic medical center experience. Cytotherapy, 2020, 22, S156-S157.	0.7	0
565	Targeting the CD6-Alcam Pathway to Prevent and Treat Graft Vs Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, S172.	2.0	0
566	NK Cell Impairment after Haploidentical Allogeneic Hematopoietic Cell Transplant in Patients Receiving Post-Transplant Cyclophosphamide (PTCy). Biology of Blood and Marrow Transplantation, 2020, 26, S70-S71.	2.0	0
567	The Y-Specific Gene PRY Is Expressed in Normal Blood Cells as Well as Leukemia Cells and Can Elicit a Specific Antibody Response in Male Recipients of Hematopoietic Stem Cells from Female Donors.. Blood, 2004, 104, 4976-4976.	1.4	0
568	PDC-E2, a Common Auto Antigen in Primary Biliary Cirrhosis (PBC) Is Also a Target of an Antibody Response in Patients Who Achieve Complete Remission after Donor Lymphocyte Infusion.. Blood, 2004, 104, 2121-2121.	1.4	0
569	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	1.4	0
570	Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.. Blood, 2004, 104, 1119-1119.	1.4	0
571	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. Blood, 2004, 104, 296-296.	1.4	0
572	ZAP-70 Expression in Acute Lymphoblastic Leukemia: Association with the E2A/PBX1 Rearrangement and with the Pre-B Stage of Differentiation.. Blood, 2004, 104, 4305-4305.	1.4	0
573	Post-Transplant Monitoring of Erythroid Lineage Specific Chimerism.. Blood, 2005, 106, 5233-5233.	1.4	0
574	Detection of the NUP214-ABL Rearrangement in T-ALL by High-Density Oligonucleotide Arrays: Evidence of the Value of This Approach in the Identification of Gene Amplifications.. Blood, 2005, 106, 1211-1211.	1.4	0
575	Identification of Target Antigens Recognized in MGUS for Immunotherapeutic Approaches.. Blood, 2005, 106, 3463-3463.	1.4	0
576	Effective Graft-Versus-Leukemia Responses Are Associated with the Presence of Nucleic Acid-Immunoglobulin Complexes That Stimulate TLR8 and TLR9.. Blood, 2006, 108, 188-188.	1.4	0

#	Article	IF	Citations
577	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAÌˆVE CD8+ T Cells. Blood, 2008, 112, 1167-1167.	1.4	0
578	Diverse Patterns of T Cell Reactivity Directed against Multiple Y Chromosome-Derived, HLA a*0201 Restricted, Peptides in Patients with chronic Gvhd. Blood, 2008, 112, 464-464.	1.4	0
579	Graft-Versus-Leukemia Antigen CML66 Elicits Coordinated B and T Cell Immunity After Donor Lymphocyte Infusion.. Blood, 2009, 114, 2449-2449.	1.4	0
580	Patterns of B Cell Activating Factor (BAFF) Levels, B Cell Recovery, and BAFF/B Cell Ratios Correlate with the Development of Chronic Graft-Versus-Host Disease (cGVHD) Following Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2011, 118, 3036-3036.	1.4	0
581	JAK1 and JAK2 Modulate Myeloma Cell Susceptibility to NK Cells Through the Interferon Gamma (IFN-Î³) Pathway,. Blood, 2011, 118, 3960-3960.	1.4	0
582	Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements,. Blood, 2011, 118, 4075-4075.	1.4	0
583	Ex Vivo Expansion of Donor-Derived Anti-Tumor T Cells for CLL-Specific Adoptive Immunotherapy. Blood, 2011, 118, 978-978.	1.4	0
584	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 1892-1892.	1.4	0
585	Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 4136-4136.	1.4	0
586	Targeting the Interferon-Î³ (IFN-Î³) Pathway to Enhance Susceptibility of Multiple Myeloma Tumor Cells to NK Cell Lysis. Blood, 2012, 120, 4013-4013.	1.4	0
587	Plasma ST2 Concentrations Predict Development of Acute Gvhd and Non-Relapse Mortality. Blood, 2012, 120, 466-466.	1.4	0
588	Enhancement of Tumor Cell Susceptibility to NK Cell Activity Through Inhibition of the PI3K Signaling Pathway.. Blood, 2012, 120, 2152-2152.	1.4	0
589	Reversal of T Cell Exhaustion in Pre-Treatment Marrow T Cells Is Associated with Effective Graft-Versus-Leukemia Responses to Donor Lymphocyte Infusion. Blood, 2012, 120, 1903-1903.	1.4	0
590	Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire. Blood, 2013, 122, 3302-3302.	1.4	0
591	Developing Novel Approaches To Comprehensively Assess T Cell Repertoire Dynamics In The Early Post-Transplant Period. Blood, 2013, 122, 4618-4618.	1.4	0
592	Quantitative and Qualitative Immune Reconstitution Following Umbilical Cord Blood Transplantation. Pancreatic Islet Biology, 2014, , 133-152.	0.3	0
593	IDENTIFICATION AND CHARACTERIZATION OF HUMAN LEUKEMIA ASSOCIATED ANTIGENS11Supported in part by NIH grant CA 34183.. , 1985, , 85-95.		0
594	Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood, 1990, 75, 296-304.	1.4	0

#	Article	IF	Citations
595	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood, 1991, 78, 2759-2767.	1.4	0
596	Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. Blood, 1992, 79, 481-488.	1.4	0
597	Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood, 1993, 81, 1651-1657.	1.4	0
598	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. Blood, 1998, 92, 2725-2729.	1.4	0
599	Prognostic Value of TREC, IL-7 and SCF Levels on Clinical Outcomes after Double Umbilical Cord Blood Transplantation in Adults. Blood, 2014, 124, 2488-2488.	1.4	0
600	Enhanced Expression of PD-1 Modulates CD4+Foxp3+ Regulatory T Cell Homeostasis during Low-Dose IL-2 Therapy in Patients with Chronic Graft-Versus-Host Disease. Blood, 2014, 124, 662-662.	1.4	0
601	Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. Blood, 2014, 124, 3961-3961.	1.4	0
602	Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells. Blood, 2014, 124, 1414-1414.	1.4	0
603	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 3425-3425.	1.4	0
604	Donor Chip Causes Donor-Derived Clonal Hematopoiesis As an Early Complication of Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 987-987.	1.4	0
605	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. Blood, 2018, 132, 817-817.	1.4	0
606	Mapping the Evolution of T Cell Transcriptional States during DLI Response and Resistance Using Single-Cell Data. Blood, 2018, 132, 821-821.	1.4	0
607	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 820-820.	1.4	0
608	Profiling T Cell Receptor Repertoires in Phase I/II Clinical Trials of Donor Treg Infusion for the Treatment of Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 4563-4563.	1.4	0
609	Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. Clinical Hematology International, 2019, 1, 201-204.	1.7	0
610	Abstract 3371: Mapping the evolution of T cell states during DLI response and resistance using single-cell data and computational tools. , 2019, , .		0
611	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). Blood, 2019, 134, 516-516.	1.4	0
612	Expression of Normal Differentiation Antigens on Human Leukemias and Lymphomas. , 1983, , 45-56.		0

#	Article	IF	Citations
613	Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. Blood, 2021, 138, 2891-2891.	1.4	0
614	Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma. Blood, 2021, 138, 75-75.	1.4	0
615	Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution. Blood, 2020, 136, 12-13.	1.4	0
616	Abstract 3371: Mapping the evolution of T cell states during DLI response and resistance using single-cell data and computational tools. , 2019, , .		0
617	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood, 1981, 58, 333-336.	1.4	0